NCT05241535View on ClinicalTrials.gov

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

February 23, 2022

Study Completion Date

February 27, 2022

Conditions
Healthy Subjects
Interventions
DRUG

MT-7117

oral

DRUG

moxifloxacin

oral

DRUG

Placebo

oral

Trial Locations (2)

32117

Daytona Beach Clinical Research Unit, Daytona Beach

75247

Dallas Clinical Research Unit, Dallas

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma America Inc.

INDUSTRY